Literature DB >> 16891248

Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.

C Emoto1, S Murase, K Iwasaki.   

Abstract

It is important to determine the cytochrome P450 (CYP) contribution of certain drugs by taking into consideration the attrition due to issues such as genetic polymorphism and inter-individual variation. In many cases in the early discovery stage, the metabolites of a new chemical have not been identified. Therefore, the present paper devised an approach in which the in vitro intrinsic clearance (CLint) value for new chemicals was determined by measuring substrate depletion. The following prediction methods were compared to calculate CLint using data from recombinant CYP enzymes: (1) the relative CYP content in human liver microsomes; (2) the relative activity factor (RAF) based on the Vmax value; and (3) the RAF value based on the CLint value. The most accurate prediction method was RAF based on CLint. This method would be useful in the early drug-discovery process in cases in which the main metabolite is not identified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891248     DOI: 10.1080/00498250600709778

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  9 in total

1.  Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.

Authors:  Kuresh A Youdim; Aref Zayed; Maurice Dickins; Alex Phipps; Michelle Griffiths; Amanda Darekar; Ruth Hyland; Odette Fahmi; Susan Hurst; David R Plowchalk; Jack Cook; Feng Guo; R Scott Obach
Journal:  Br J Clin Pharmacol       Date:  2008-02-14       Impact factor: 4.335

2.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

Review 3.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

Review 4.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

Review 5.  In vitro platforms for evaluating liver toxicity.

Authors:  Shyam Sundhar Bale; Lawrence Vernetti; Nina Senutovitch; Rohit Jindal; Manjunath Hegde; Albert Gough; William J McCarty; Ahmet Bakan; Abhinav Bhushan; Tong Ying Shun; Inna Golberg; Richard DeBiasio; Berk Osman Usta; D Lansing Taylor; Martin L Yarmush
Journal:  Exp Biol Med (Maywood)       Date:  2014-04-24

6.  Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies.

Authors:  O B Usta; W J McCarty; S Bale; M Hegde; R Jindal; A Bhushan; I Golberg; M L Yarmush
Journal:  Technology (Singap World Sci)       Date:  2015-03

7.  Combining structure- and ligand-based approaches to improve site of metabolism prediction in CYP2C9 substrates.

Authors:  Laura J Kingsley; Gregory L Wilson; Morgan E Essex; Markus A Lill
Journal:  Pharm Res       Date:  2014-09-11       Impact factor: 4.200

Review 8.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

9.  Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.

Authors:  Muhammad Nasir Kalam; Muhammad Fawad Rasool; Faleh Alqahtani; Imran Imran; Asim Ur Rehman; Naveed Ahmed
Journal:  Drug Des Devel Ther       Date:  2021-03-17       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.